MicroRNA-208b inhibits human osteosarcoma progression by targeting ROR2

Abstract

MicroRNAs are widely involved in cancer progression by inhibiting the expression levels of oncogenes or tumor suppressor genes, and dysregulation of microRNAs may contribute to tumorigenesis. Here, we found that overexpressed miR-208b can reduce the proliferation of human osteosarcoma cell lines U-2OS and Saos-2 by arresting cell cycle progression. The in vivo xenograft tumors induced by Saos-2 cells overexpressing miR-208b had smaller size and grew more slowly than those induced by the control cells. The mobility of U-2OS or Saos-2 cells was also downregulated by miR-208b. MiR-208b targeted a site in the 3′ untranslated region of receptor tyrosine kinase–like orphan receptor 2. Inhibition of receptor tyrosine kinase–like orphan receptor 2 suppresses osteosarcoma metastasis in vitro. Recovering the expression levels of receptor tyrosine kinase–like orphan receptor 2 in miR-208b-overexpressed U-2OS or Saos-2 cells attenuated the inhibitory effects of miR-208b. In addition, the expression levels of miR-208b are significantly reduced in human osteosarcoma tissue samples compared to normal tissue samples, and miR-208b levels correlated inversely with receptor tyrosine kinase–like orphan receptor 2 levels. On these bases, we identified that miR-208b targets receptor tyrosine kinase–like orphan receptor 2 gene by which miR-208b can regulate the development of osteosarcoma.

Keywords

Cell proliferation cell motor abilities miR-208b receptor tyrosine kinase–like orphan receptor 2 osteosarcoma

Introduction

Osteosarcoma (OS) is one of the most frequent primary sarcoma of the skeleton in children, adolescents, and young adults, and it is a kind of destructive malignant tumors.¹ Surgery was the only method to treat OS before 1970s. The cure rate was low, and the mortality rate was about 80&x37;. In 1970s, chemotherapy came out, providing a new treatment option for patients with OS. Benefited from the new therapy, the livability increased from about 20% to 65%–70%.² To date, multi-agent chemotherapy is a common therapeutic option for the OS as it has a high tendency to metastasize.^3,4 So more effective treatment methods with much fewer side effects still need to be improved in the future.

MicroRNAs (miRNAs) are highly conserved, very short non-coding nucleic acid chains comprising 18 to 24 nucleotides, which are naturally produced by the genome. MiRNAs cannot be translated into proteins or oligopeptides, and they generally suppress gene expression at the post-transcriptional level.⁵ In general, the 3′ untranslated region (3′-UTR) of messenger RNAs (mRNAs) can provide target sites for miRNAs.⁶ In the cytoplasm, RNA-induced silencing complex (RISC) containing mature miRNAs can bind to the messenger RNAs ⁷ and block the mRNA translating into protein or speed-up the degradation of the mRNA via binding to the target sites of mRNAs in various biological processes.⁸ In recent years, some studies indicate that miRNAs may contribute to the inhibition of cancer. For example, miR-22 has a directed target: adenosine triphosphate (ATP) citrate lyase. The expression level of miR-22 and tumor growth and metastasis show a negative correlation.⁹ However, some miRNAs contribute to the development of cancer. For example, miR-21 contributes to the development of human laryngeal carcinoma by binding to the target site of BTG2.¹⁰ These findings show that miRNAs have certain regulation functions in the development of tumor. The researches on miRNAs can provide a new perspective for establishing new therapies. Bian et al.¹¹ showed that miR-208b-3p was downregulated by luteolin, which inhibits ischemia/reperfusion (I/R)-induced myocardial injury. Guo et al.¹² found that curcumin can increase cyclin-dependent kinase inhibitor 1A (CDKN1A) by downregulating miR-208 to inhibit growth of prostate carcinoma. However, the exact function of miR-208b in OS progression remains unclear.

Receptor tyrosine kinase–like orphan receptor 2 (ROR2) is a member of the receptor tyrosine kinase (RTK) family that regulate cell proliferation, polarity, differentiation, migration, metabolism, and survival.^13,14 Lu et al.¹⁵ investigated WNT-5a and ROR2 expression using immunohistochemistry in 42 OS and 12 osteochondroma specimens and reported that expression of both WNT-5a and ROR2 was correlated with Enneking surgical stage and tumor metastasis. ROR2 could enhance cell migration, and the WNT5B/ROR2 signaling pathway is a potential therapeutic target for OS.¹⁶

In this study, we used molecular biology and cell biology methods to determine the role of miR-208b in the regulation of OS. The regulating effect of miR-208b on OS was identified by various experimental methods in vivo or in vitro. We explored the regulating effect of miR-208b on OS progression and confirmed a functional target—ROR2—for miR-208b in OS cells.

Experimental procedures

Clinical tumor specimens

A total of 15 OS samples were obtained from Jilin Central Hospital. All the samples were obtained with the patients’ informed consent and approved by the Research Ethics Committee of Jilin Central Hospital.

Cell culture and transfection

Human OS cell lines Saos-2 and U-2OS were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA). Cultures of the cell lines were maintained in a humidified, 37°C, 5% CO₂ incubator. McCoy’s 5A Media (modified with tricine; Sigma, St. Louis, MO, USA) with 10% fetal bovine serum (FBS; Gibco, Carlsbad, CA, USA) was used for cell culture. To generate the protein overexpression, the coding sequences of ROR2 without 3′-UTR were cloned into pcDNA3.0 (+). Transfections were performed with the Lipofectamine 2000 Reagent (Invitrogen, Waltham, MA, USA) following the manufacturer’s protocols.

Cell proliferation assay

The cell counting kit-8 (CCK-8; Dojindo Laboratories, Kumamoto, Japan) was used for proliferation assay. A volume of 1 × 10³ U-2OS or Saos-2 cells treated with miRNA-208b mimics or miRNA control were cultured on 96-well culture plates for 6, 12, 24, or 48 h. After adding 10 µL of the CCK-8 solution to each well, cells were incubated at 37°C for 2 h. A Multiskan GO (Thermo Fisher Scientific, Vantaa, Finland) was used for recording the optical density values at 450 nm.

Cell migration and invasion assays

Transwell chambers (Millipore, Billerica, MA, USA) were used for invasion assays. After transfection, 1 × 10⁵ cells in 50 µL FBS-free Dulbecco’s Modified Eagle’s Medium (DMEM) were added to the upper chamber containing 50 µL Matrigel. A volume of 450 µL DMEM containing 10% FBS was placed into the lower chamber. The cells in 24 well-plates with transwell chambers were cultured in a humidified atmosphere for 24 h at 37°C with 5% CO₂. When the tumor cells located on the bottom surface of the membrane, 100% methanol was used for fixing. After 30 min, the cells were stained by 0.5% crystal violet (Sigma-Aldrich, St Louis, MO, USA) for 20 min and then counted under a phase-contrast microscope (Olympus, Tokyo, Japan). Similar to invasion assays, migration assays were executed with 24-well plates without Matrigel.

Cell cycle analysis

Cells were cultured for 2 days after transfection. The cells were fixed with ice-cold 95% ethanol, and propidium iodide/RNase buffer (BD Biosciences, NJ, USA) was used for cell staining. The cells were analyzed by flow cytometry after incubating for 30 min at 4°C in dark.

Quantitative reverse transcription polymerase chain reaction

Total RNA was extracted from cultured cells or tissue samples using TRIzol reagent (Invitrogen). To get complementary DNA (cDNA), reverse transcription (2 µg of total RNA was used to synthesize cDNA) was performed using the miScript II RT Kit (Qiagen, Valencia, CA, Denmark). Then, quantitative reverse transcription polymerase chain reaction (qRT-PCR) of miRNA was carried out using a SYBR PrimeScript miRNA RT-PCR Kit (TaKaRa, Otsu, Japan). U6 was used for normalization. The expression levels of ROR2 mRNA were quantified using the SYBR Green PCR core reagents (Bio-Rad Laboratories, Hercules, CA, USA) at the following reaction conditions: 95°C for 2 min, 40 cycles of denaturation at 95°C for 25 s, primer annealing at 60°C for 25 s, and extension at 72°C for 20 s. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) served as an internal control, and the relative mRNA expression was calculated using 2^−ΔCt method.

Western blot analysis

Cells were scraped from the wells, and total proteins were extracted using ice-cold radioimmunoprecipitation assay (RIPA) lysis buffer (Solarbio, Beijing, China) with protease inhibitor. Total proteins were separated on 12% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to nitrocellulose membrane (Bio-Rad Laboratories). The membrane was then blocked with 5% non-fat milk and incubated with the primary antibodies (Abcam, Cambridge, UK). The membranes were washed and treated with a horseradish peroxidase–conjugated secondary antibody subsequently (ICL Lab, Portland, Oregon, USA). After washing with Tris-buffered saline (TBS), the bands were visualized by chemiluminescence (Millipore). The strength of GAPDH bands was regarded as the standard.

Statistical analysis

The numerical results are presented as mean ± standard deviation. Statistical significance between groups was determined by one-way analysis of variance (ANOVA). Statistically significant differences of p < 0.05 were considered.

Results

MiR-208b suppresses OS progression both in vitro and in vivo

Previous study showed that miR-208b expression significantly decreased in OS cells.¹⁷ To explore the role of miR-208b in OS development, transfection with miR-208b mimics was executed and progress of tumor was tested both in vitro and in vivo. The efficiency of miR-208b was confirmed by qRT-PCR in the OS cells—U-2OS and Saos-2 (Figure 1(a)). The overexpression of miR-208b negatively regulated the proliferation of U-2OS and Saos-2 cells (Figure 1(b) and (c)). After miR-208b transfection, the colony number reduced from 56 ± 7.3 to 26 ± 4.9 in U-2OS and from 51.5 ± 9.1 to 27.8 ± 3.2 in Saos-2 (Figure 1(b)) cells. Cell viability weakened in both U-2OS and Saos-2 at different time points of treatment (Figure 1(c)). Following miR-208b mimics transfection, the proportion of cells in G1 phase increased significantly, indicating a G1 arrest (Figure 1(d)). To further compare the proliferation, Western blotting was performed subsequently. Our results showed that the expression of proliferation-associated genes cyclin E and cyclin D1 was downregulated in both the miR-208b-treated U-2OS and Saos-2 cells. However, the expression of CDK4 was not significantly altered (Figure 1(e)).

Figure 1.

Inhibiting effects of miR-208b on osteosarcoma progression. (a) U-2OS and Saos-2 cells were treated with miR-208b mimics, and expression level of miR-208b in U-2OS and Saos-2 cells was detected by quantitative PCR. (b) The proliferation of U-2OS and Saos-2 cells was detected by colony formation assay. (c) Viabilities of U-2OS and Saos-2 cells were detected by CCK-8 cell proliferation assay at different time points. (d) Cell cycle distribution was analyzed by flow cytometry. (e) Cyclin E, Cyclin D1, and CDK4 protein levels were detected by Western blotting. (f) Hypodermic implantation of Saos-2 cells infected with control vector or miR-208b mimics was performed to build the osteosarcoma mouse model. The size of subcutaneous tumors in these two groups was calculated and compared (*p < 0.05; **p < 0.01).

We also built subcutaneously implanted models of Saos-2 cells. After 14 days of implantation, the sizes of tumors were measured at various time points. Our results showed that tumors induced by the cells overexpressing miR-208b had smaller size and grew more slowly than those induced by the scramble cells (Figure 1(f)).These findings suggest that miR-208b has a negative role in tumor progression both in vivo and in vitro.

MiR-208b suppresses motor abilities in both U-2OS and Saos-2 cells

To study the effect of miR-208b on motor abilities of tumors, the migration and invasion assays were performed. According to the results, the motor abilities of U-2OS and Saos-2 cells were inhibited by overexpression of miR-208b (Figure 2(a) and (b)). The migration of U-2OS and Saos-2 cells was measured after being cultured for 24 h (Figure 2(a)). The results show that the cell migration was inhibited in both U-2OS and Saos-2 cells treated with miR-208b mimics. In addition, the cell number was counted in the invasion assays, and overexpression of miR-208b suppressed the cell invasion (Figure 2(b)). The expression of motor ability related genes was detected subsequently, and the expression of C-MYC and p-JNK was restrained in both U-2OS and Saos-2 cells treated with miR-208b mimics (Figure 2(c)). Our results show that overexpressed miR-208b can inhibit motor abilities of the OS cell lines.

Figure 2.

MiR-208b inhibits motor abilities of U-2OS and Saos-2 cells. (a) Migration and (b) invasion of U-2OS and Saos-2 cells were detected. The average number of invasive cells per field was counted. (c) C-MYC and p-JNK protein levels were detected by Western blotting (*p < 0.05; **p < 0.01).

MiR-208b targets ROR2 and inhibits its expression

Bioinformatics tool TargetScan was used for forecasting the putative miR-208b targets, and miR-208b has a predictive target—ROR2 (Figure 3(a)). Then, luciferase reporters with wild-type or mutated ROR2 3′-UTR were constructed for further research (Figure 3(a)). The results of the luciferase reporter assay showed that the luciferase activities of the wild-type vector were decreased in both U-2OS and Saos-2 cells treated with miR-208b mimics. No statistically significant differences in the luciferase activities were observed in mutant vectors (Figure 3(b)). Western blot analysis was performed to measure the protein expression of ROR2, subsequently (Figure 3(c)). The results showed that ROR2 was downregulated after being transfected with miR-208b mimics in both U-2OS and Saos-2 cells. So, ROR2 was a target gene of miR-208b, and miR-208b can downregulate ROR2.

Figure 3.

MiR-208b targets ROR2 and represses ROR2 expression by binding to its 3′-UTR. (a) MiR-208b has a predictive target, ROR2, forecasted by the bioinformatics tool TargetScan. (b) Luciferase activities in the U-2OS and Saos-2 cells transfected with reporter vectors bearing wild-type (wt) or mutated (mut) miR-208b binding site were detected. (c) ROR2 protein level in the U-2OS and Saos-2 cells transfected with miR-208b mimics was detected by Western blotting (*p < 0.05; **p < 0.01).

Inhibition of ROR2 suppresses OS metastasis in vitro

The role of ROR2 on progression of OS cell lines was studied by small interfering RNA (siRNA). When transfected with ROR2-siRNA, the ROR2 protein levels declined significantly (Figure 4(a)). The results of CCK-8 assay showed that silencing ROR2 suppresses the proliferation of OS cells (Figure 4(b)). After ROR2 was inhibited, the motor abilities of U-2OS and Saos-2 cells were inhibited (Figure 4(c) and (d)). After ROR2 was overexpressed, the motor abilities of U-2OS and Saos-2 cells were accelerated (Figure 4(e) and (f)). All these indicated that ROR2 promotes OS metastasis.

Figure 4.

Silencing ROR2 represses osteosarcoma cell migration and invasion. (a) ROR2 protein level in U-2OS and Saos-2 cells transfected with ROR2-siRNA infection was detected by Western blotting. (b) Viabilities of U-2OS and Saos-2 cells were detected by CCK-8 cell proliferation assay at different time points after transfection. (c) Migration and (d) invasion of U-2OS and Saos-2 cells transfected with ROR2-siRNA were detected. (e) Migration and (f) invasion of U-2OS and Saos-2 cells transfected with pcDNA3.0-ROR2 were detected (**p < 0.01; siRNA: small interfering RNA).

MiR-208b mediates OS metastasis by targeting ROR2

MiR-208b binds to the predicted ROR2 3′-UTR binding site which was demonstrated in the previous experiments (Figure 3). So, we have provided a compensatory ROR2 expression by exogenous pcDNA3.0-ROR2, and the effectiveness was detected by Western blot analysis (Figure 5(a)). Then, we detected the proliferation and migration of cells with or without ROR2 or miR-208b overexpression (Figures 5(b)–(e)). The proliferation was increased by ROR2 overexpression, but the overexpression of miR-208b offsets the effect of ROR2 in proliferation (Figure 5(b)). We silenced the endogenous ROR2 expression by overexpressing miR-208b in both U-2OS and Saos-2 cells, and the motor abilities were upregulated after compensatory ROR2 expression by exogenous pcDNA3.0-ROR2 (Figure 5(c) and (d)). Western blot analysis was therewith used for detecting the protein expression levels of the genes related to proliferation and migration (Figure 5(e)). The results showed that the protein expression levels were upregulated generally after compensatory ROR2 expression in both U-2OS and Saos-2 cells. These results demonstrated that miR-208b can restrain OS metastasis by targeting ROR2.

Figure 5.

ROR2 is involved in the regulation of osteosarcoma metastasis by miR-208b. (a) ROR2 protein level in the osteosarcoma cells after pcDNA3.0, pcDNA3.0-ROR2, pcDNA3.0-ROR2+miRNA con, and pcDNA3.0-ROR2+miR-208b transfection was detected by Western blotting. (b) Viabilities of U-2OS and Saos-2 cells were detected by CCK-8 cell proliferation assay at different time points after infection. (c) Migration and (d) invasion of transfected U-2OS and Saos-2 cells were detected. (e) Cyclin E, C-myc, p-JNK, Cyclin D1, and CDK4 protein levels were detected by Western blotting (*p < 0.05; **p < 0.01).

The clinical OS has a higher expression level of ROR2 and a lower expression level of miR-208b

Immunohistochemical staining was performed in clinical OS tissues (Figure 6(a)). The number of ROR2-positive cells in OS tissues was more than that in normal tissues. To explore the role of miR-208b-ROR2 regulation in tumor, quantitative PCR (qPCR) was performed in both the OS tissues and benign tissues (including giant cell tumor I also known as GCT I and GCT II–III and synovial osteochondroma also known as SOC; Figure 6(b) and (c)). The results showed that in OS, the level of miR-208b was downregulated, but the level of ROR2 was upregulated. Then, the protein expression levels of ROR2 were detected in GCT I, GCT II–III, SOC, and OS (Figure 6(d)). We found that the level of ROR2 was upregulated in OS. These results were consistent with the demonstrations given above.

Figure 6.

Low miR-208b level activates ROR2 expression in human osteosarcoma tissues. (a) ROR2 in osteosarcoma tissues was detected by immunohistochemical staining (scale bars: 20 µm). (b) miR-208b and (c) ROR2 expression levels in the osteosarcoma tissues and benign tumor tissues (including GCT I, GCT II–III, and SOC) were detected by qPCR. (d) ROR2 protein levels in the osteosarcoma tissues and benign tumor tissues were detected by Western blotting (*p < 0.05).

Discussion

OS is a sarcoma of the bone which is a common primary malignant bone tumor in children, adolescents, and young adults.¹ Until recent years, due to the use of multi-agent chemotherapy and other treatment means, the overall survival of localized OS is above 70%.^3,4 However, prognosis is unfavorable due to OS recurrence and metastasis. So treatment methods still need to be improved in the future. In our study, we used molecular biology and cell biology methods to determine the role of miR-208b in the regulation of OS. The regulating effect of miR-208b on OS was identified by various experimental methods in vivo or in vitro. Exogenous miR-208b can reduce the proliferation of U-2OS or Saos-2 cells in vitro, and the tumor cells overexpressing miR-208b showed a slow growth rate in vivo. Furthermore, we also proved that overexpression of miR-208b obviously decreased proliferation by arresting cell cycle in G1 phase. In addition, the mobility of U-2OS or Saos-2 cells was downregulated by the overexpression of miR-208b. ROR2 was downregulated after being transfected with miR-208b mimics in both U-2OS and Saos-2 cells. After ROR2 was inhibited, the motor abilities of U-2OS and Saos-2 cells were inhibited. Other than that, miR-208b level was significantly reduced in human OS tumor cells compared to carcinoid cells (GCT I, GCT II–III, and SOC). Here, we show evidence that miR-208b suppresses OS progression by targeting a site in 3′-UTR of ROR2.

Both knockdown of ROR2 gene by ROR2-siRNA and overexpression miR-208b can depress the progression of OS. The inhibition by overexpressed miR-208b can be relieved by exogenous supply of ROR2. Besides the decreased expression of miR-208b, the ROR2 expression levels were upregulated in human OS tissue samples. The findings of this study are consistent with previous studies. ROR2 is a member of the RTK family that regulates cell proliferation, polarity, differentiation, migration, metabolism, and survival.^13,14 Huang et al.¹⁸ found that knockdown of ROR2 suppresses OS cell proliferation and colony formation. Morioka et al.¹⁶ found that the physiological interaction of WNT5B and ROR2 could enhance cell migration, and the WNT5B/ROR2 signaling pathway is a potential therapeutic target for OS. Li et al.¹⁹ identified that ROR2 is an epigenetically inactivated tumor suppressor gene and antagonizes both β-catenin and AKT signaling in multiple tumorigenesis. On these bases, we identified that ROR2 gene joins in the development of OS.

Our results showed that the overexpression of miR-208b can effectively inhibit the expression levels of endogenous ROR2 gene in both U-2OS and Saos-2 cells. MiR-208b was involved in regulating OS development by binding to a target site in the ROR2-3′UTR. Furthermore, we also proved that overexpression of miR-208b obviously decreased proliferation by arresting cell cycle in G1 phase. Previous reports indicate that miRNAs play a role in cancer progression.^20–25 MiRNA-497 acts as a negative regulator in human OS progression, and it has a target site in AMOT gene.²⁶ MiR-495 that targets Akt1 can inhibit esophageal squamous cell carcinoma progression.²⁷ Collectively, these data suggested that miR-208b can target ROR2 and inhibit OS progression by inducing cell cycle arrest.

MiRNAs are required for various biological processes. Overexpression of miR-208b can improve myocardial functions via GATA4, and miR-208b plays a protective role in post-infarction myocardial fibrosis.²⁸ What is interesting is that miRNAs also take part in skin development and neural development. Wang et al.²⁹ identified that miR-205 can mediate the repression of phospho-Akt and restrict the proliferation of skin stem cells by targeting and modulating the phosphoinositide 3-kinase (PI3K) pathway. MiR-219 and miR-338 are required for oligodendrocyte differentiation and play their role via SOX6 and HES5.^30,31 Although there are many studies about miRNAs, more research is needed to apply to clinical application.

Taken together, our studies support that ROR2 is a target gene for miR-208b. MiR-208b was downregulated in OS and was negatively correlated with ROR2. MiR-208b inhibits OS progression by targeting ROR2. New therapies based on miRNAs that have fewer complications should be researched further.

Footnotes

Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Scientific Research Project in the Science and Technology Development Plan of Jilin Province (20120941).

References

Picci

. Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis 2007; 2: 6.

Allison

Carney

Ahlmann

. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012: 704872.

Meyers

Schwartz

Krailo

. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005; 23(9): 2004–2011.

Ferrari

Smeland

Mercuri

. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol 2005; 23(34): 8845–8852.

Ambros

. The functions of animal microRNAs. Nature 2004; 431(7006): 350–355.

Bartel

. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116(2): 281–297.

Borchert

Lanier

Davidson

. RNA polymerase III transcribes human microRNAs. Nat Struct Mol Biol 2006; 13(12): 1097–1101.

Mendell

Olson

. MicroRNAs in stress signaling and human disease. Cell 2012; 148(6): 1172–1187.

Xin

Qiao

. miR-22 inhibits tumor growth and metastasis by targeting ATP citrate lyase: evidence in osteosarcoma, prostate cancer, cervical cancer and lung cancer. Oncotarget 2016; 7: 44252–44265.

10.

Liu

. Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma. Cell Res 2009; 19(7): 828–837.

11.

Bian

Zhu

. Luteolin inhibits ischemia/reperfusion-induced myocardial injury in rats via downregulation of microRNA-208b-3p. PLoS ONE 2015; 10(12): e0144877.

12.

Guo

. Curcumin inhibits growth of prostate carcinoma via miR-208-mediated CDKN1A activation. Tumour Biol 2015; 36(11): 8511–8517.

13.

Ullrich

Schlessinger

. Signal transduction by receptors with tyrosine kinase activity. Cell 1990; 61(2): 203–212.

14.

Blume-Jensen

Hunter

. Oncogenic kinase signalling. Nature 2001; 411(6835): 355–365.

15.

Wang

Wei

. Expression of WNT-5a and ROR2 correlates with disease severity in osteosarcoma. Mol Med Rep 2012; 5(4): 1033–1036.

16.

Morioka

Tanikawa

Ochi

. Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma. Cancer Sci 2009; 100(7): 1227–1233.

17.

Zhao

. MiR-133b is down-regulated in human osteosarcoma and inhibits osteosarcoma cells proliferation, migration and invasion, and promotes apoptosis. PLoS ONE 2013; 8(12): e83571.

18.

Huang

Shi

. Knockdown of receptor tyrosine kinase-like orphan receptor 2 inhibits cell proliferation and colony formation in osteosarcoma cells by inducing arrest in cell cycle progression. Oncol Lett 2015; 10(6): 3705–3711.

19.

Ying

Tong

. Epigenetic identification of receptor tyrosine kinase-like orphan receptor 2 as a functional tumor suppressor inhibiting beta-catenin and AKT signaling but frequently methylated in common carcinomas. Cell Mol Life Sci 2014; 71(11): 2179–2192.

20.

Wang

Chen

. miR-197: a novel biomarker for cancers. Gene 2016; 591: 313–319.

21.

Liang

Bian

Shim

. Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun 2016; 477(3): 461–466.

22.

Orso

Quirico

Virga

. miR-214 and miR-148b targeting inhibits dissemination of melanoma and breast cancer. Cancer Res 2016; 76: 5151–5162.

23.

Penna

Orso

Cimino

. microRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011; 30(10): 1990–2007.

24.

Stark

Bonazzi

Boyle

. miR-514a regulates the tumour suppressor NF1 and modulates BRAFi sensitivity in melanoma. Oncotarget 2015; 6(19): 17753–17763.

25.

Stark

Tom

Boyle

. The “melanoma-enriched” microRNA miR-4731-5p acts as a tumour suppressor. Oncotarget 2016; 7: 49677–49687.

26.

Ruan

Wang

Feng

. MicroRNA-497 inhibits cell proliferation, migration, and invasion by targeting AMOT in human osteosarcoma cells. Onco Targets Ther 2016; 9: 303–313.

27.

Mao

Liu

. MiR-495 inhibits esophageal squamous cell carcinoma progression by targeting Akt1. Oncotarget 2016; 7: 51223–51236.

28.

Zhou

Cui

. MicroRNA-208b alleviates post-infarction myocardial fibrosis in a rat model by inhibiting GATA4. Med Sci Monit 2016; 22: 1808–1816.

29.

Wang

Zhang

O’Loughlin

. MicroRNA-205 controls neonatal expansion of skin stem cells by modulating the PI(3)K pathway. Nat Cell Biol 2013; 15(10): 1153–1163.

30.

Dugas

Cuellar

Scholze

. Dicer1 and miR-219 are required for normal oligodendrocyte differentiation and myelination. Neuron 2010; 65(5): 597–611.

31.

Zhao

Han

. MicroRNA-mediated control of oligodendrocyte differentiation. Neuron 2010; 65(5): 612–626.